HGF/Met signaling promotes biological activities, resulting in tumor growth, angiogenesis and the development of invasive phenotypes, making this receptor an attractive target for the potential anti-cancer treatment of NSCLC [6]–[8]. The gene discussed is HGF; the disease is cancer.